Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission
Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
- You are here:
- Home »
- Blog »
- Multiple Myeloma »
- Microbiome Testing for Myeloma
Microbiome Testing for Myeloma
Gut microbiome testing for myeloma patients is another form of prehabilitation. That is to say, the MM patient’s gut health, according to research linked below, is related to the patient’s response to treatment and risk of side effects.
The challenge is to figure out if our gut microbiome is healthy or not. That’s where microbiome testing for myeloma comes in. The info below walks the newly diagnosed myeloma patient through the testing process.
1. Major Testing Platforms and What They Offer
| Test Name | Type / Method | Key Strengths | Possible Myeloma-Relevant Insights |
|---|---|---|---|
| Genova Diagnostics – GI Effects® Comprehensive Stool Profile | DNA-based (16S rRNA and culture) | Measures diversity, inflammation markers (calprotectin, SCFA levels, β-glucuronidase) | Identifies butyrate producers, dysbiosis, inflammation, and digestive insufficiency — useful pre- or post-ASCT |
| Viome Full Body Intelligence / Gut Intelligence Test | Metatranscriptomic (RNA sequencing) | Measures microbial activity(not just presence) and host-microbe interaction | Identifies pathways related to inflammation, oxidative stress, and mucosal immunity; helps guide anti-inflammatory dietary choices |
| Thryve (now Ombre) | 16S rRNA sequencing | Consumer-friendly, trend tracking over time | Highlights deficits in SCFA producers, fiber fermenters, or immune-supportive microbes |
| BiomeFx (Microbiome Labs) | Shotgun metagenomics | Quantitative and functional; excellent resolution to species level | Detects butyrate-producing pathways, microbial metabolites relevant to immune regulation, and antibiotic impact |
| Onegevity / Nutrigenomix | Metagenomics plus nutrient metabolism profiling | Integrates microbiome with genetic data | Useful for nutrition personalization during dexamethasone therapy (metabolic and glycemic control) |
2. Interpreting Key Findings in the Myeloma Context
Below is a guide for clinically relevant findings from these tests and how they can inform management:
| Finding | What It Means | Possible Actions / Interventions |
|---|---|---|
| ↓ Faecalibacterium prausnitzii, Eubacterium hallii, Roseburia spp. | Low butyrate production, reduced anti-inflammatory tone | Increase soluble fiber (inulin, resistant starch), consider Butyricicoccus pullicaecorum-based probiotic or prebiotic formula |
| ↓ Diversity / ↑ Enterobacteriaceae | Dysbiosis, often post-antibiotic or steroid use | Gradual fiber reintroduction, kefir/yogurt, targeted probiotic blends (multi-strain Lactobacillus and Bifidobacterium) |
| ↑ Candida or other fungi | Antibiotic-associated fungal overgrowth | Consider antifungal foods (garlic, caprylic acid from coconut), avoid excessive simple sugars |
| Low SCFA or elevated β-glucuronidase | Mucosal inflammation or toxin reabsorption | Support gut barrier: glutamine, zinc carnosine, omega-3, avoid unnecessary NSAIDs |
| Low Akkermansia muciniphila | Impaired mucosal layer, reduced immune signaling | Add polyphenol-rich foods (pomegranate, green tea), consider pasteurized A. muciniphila supplements (available in EU; limited in US) |
| Low diversity pre-transplant | Predicts delayed immune recovery | Begin microbiome restoration plan pre-ASCT (fiber, limited antibiotics, probiotic protocol under oncologist guidance) |
3. Timing for Myeloma Patients
| Treatment Phase | Testing Timing | Why It Matters |
|---|---|---|
| Baseline (diagnosis or pre-treatment) | Before lenalidomide or bortezomib start | Establishes baseline diversity, identifies risk for GI or immune complications |
| Pre-ASCT | 1–2 months before stem cell collection | Guides interventions to boost diversity before high-dose chemo |
| Post-ASCT | 3–6 weeks post-engraftment | Evaluates recovery of microbial diversity and readiness for dietary reintroduction |
| Maintenance phase | Every 6–12 months | Monitors stability and detects chronic inflammation or dysbiosis early |
4. Integrative Use with Standard-of-Care
Microbiome test results can complement clinical management by:
-
Coordinating with oncology nutritionists for high-fiber, low-inflammatory diet plans.
-
Guiding probiotic use safely (avoiding live probiotics during neutropenia).
-
Reducing GI toxicity during IMiD or proteasome inhibitor therapy.
-
Enhancing immune readiness post-transplant or during maintenance.
5. Practical Caveats
-
Results must be interpreted in clinical context—they do not replace standard labs or imaging.
-
No probiotic or prebiotic should be started during neutropenia unless under supervision.
-
Focus should be on restoring natural diversity via diet before supplements whenever possible.
Immune health and gut health are both examples of issues that directly contribute to the overall survival of newly diagnosed MM patients, but that are not discussed by oncologists with their patients.
If you have any questions about managing your MM, scroll down the page, post a question or comment and I will reply to you ASAP.
Thanks,
David Emerson
- MM Survivor
- MM Cancer Coach
- Director PeopleBeatingCancer
Gut microbiome in multiple myeloma: Mechanisms of progression and clinical applications
Abstract
The gut commensal microbes modulate human immunity and metabolism through the production of a large number of metabolites, which act as signaling molecules and substrates of metabolic reactions in a diverse range of biological processes.
There is a growing appreciation for the importance of immunometabolic mechanisms of the host-gut microbiota interactions in various malignant tumors. Emerging studies have suggested intestinal microbiota contributes to the progression of multiple myeloma.
In this review, we summarized the current understanding of the gut microbiome in MM progression and treatment, and the influence of alterations in gut microbiota on treatment response and treatment-related toxicity and complications in MM patients undergoing hematopoietic stem cell transplantation (HSCT).
Furthermore, we discussed the impact of gut microbiota-immune system interactions in tumor immunotherapy, focusing on tumor vaccine immunotherapy, which may be an effective approach to improve anti-myeloma efficacy…
Conclusion
In conclusion, the gut commensal microbiota is critical in regulating the function of the immune system, and several studies have shown a significant role for the gut microbiota in MM pathogenesis and progression by influencing inflammatory pathways and host metabolism.
Gut microbial metabolites can influence host immunity, and in particular, the most studied SCFAs may significantly influence the outcome for patients with MM.
After auto-HSCT, higher gut microbiota diversity linked with better outcomes, which may be a rationale for avoiding injury to the microbiota through judicious use of broad-spectrum antibiotics.
Recent studies suggest that gut microbes may influence vaccine efficacy, including the ability of antigens to elicit protective immune responses and the ability of the immune system to respond properly to antigenic stimulation, by acting as immunomodulators and natural vaccine adjuvants.
Thus, it seems highly probable that there is a role of the gut microbiota in combination with vaccine immunotherapy for MRD in MM after receiving HSCT. Despite the important role of the microbiota in modulating the vaccine immune response, further investigations are needed to definitively demonstrate this possibility.